Eton Pharmaceuticals Inc Quick Ratio (ETON) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Eton Pharmaceuticals Inc   (NASDAQ: ETON)

Eton Pharmaceuticals Inc 's Quick Ratio

ETON's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Eton Pharmaceuticals Inc 's Cash & cash equivalent grew by 36.54 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Eton Pharmaceuticals Inc 's Quick Ratio to 0.59, Quick Ratio remained below Eton Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 383 other companies have achieved higher Quick Ratio than Eton Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 2305, from total ranking in the first quarter 2026 at 2408.

Explain Quick Ratio?
How much Cash & cash equivalents ETON´s has?
What are ETON´s Current Liabilities?




ETON Quick Ratio (Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
(Jun 30 2025)
Q2
Y / Y Current Liabilities Change 16.91 % 74.28 % 92.96 % 123.89 % 111.88 %
Y / Y Cash & cash equivalent Change 5.78 % 12.86 % 73.69 % 83.21 % 43.43 %
Quick Ratio MRQ 0.59 0.45 0.67 0.84 0.66
ETON's Total Ranking # 2305 # 2408 # 2128 # 1169 # 1699
Seq. Current Liabilities Change 2.14 % 14.78 % -12.89 % 14.48 % 52.25 %
Seq. Cash & cash equivalent Change 36.54 % -24.21 % -30.12 % 46.27 % 45.69 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 384
Healthcare Sector # 715
Overall Market # 2305


Quick Ratio Statistics
High Average Low
16.59 4.31 0.45
(Dec 31 2018)   (Mar 31 2026)




Financial Statements
Eton Pharmaceuticals Inc 's Current Liabilities $ 45 Millions Visit ETON's Balance sheet
Eton Pharmaceuticals Inc 's Cash & cash equivalent $ 27 Millions Visit ETON's Balance sheet
Source of ETON's Sales Visit ETON's Sales by Geography


Cumulative Eton Pharmaceuticals Inc 's Quick Ratio

ETON's Quick Ratio for the trailling 12 Months

ETON Quick Ratio

(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
(Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 65.96 % 98.74 % 100.31 % 94.46 % 83.34 %
Y / Y Cash & cash equivalent TTM Growth 40.48 % 53.75 % 52.22 % 24.81 % 0.24 %
Quick Ratio TTM 0.64 0.65 0.72 0.74 0.75
Total Ranking TTM # 4101 # 2970 # 2500 # 2138 # 2903
Seq. Current Liabilities TTM Growth 3.95 % 12.84 % 14.48 % 23.59 % 24.48 %
Seq. Cash & cash equivalent TTM Growth 1.36 % 2.12 % 11.6 % 21.62 % 10.93 %


On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $45.12 millions, cumulative Quick Ratio decreased to 0.64 below the Eton Pharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Eton Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2970 to 4101.

Explain Quick Ratio?
How much Cash & cash equivalents ETON´s has?
What are ETON´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 907
Within the Market # 4101


trailing twelve months Quick Ratio Statistics
High Average Low
8.48 3.31 0.64
(Sep 30 2019)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions
Revium Rx.  1.55 $ 1.506  Millions$ 0.971  Millions
Liquidia Corporation  1.50 $ 284.181  Millions$ 189.298  Millions
Greenwich Lifesciences Inc   1.50 $ 8.876  Millions$ 5.923  Millions
Arcutis Biotherapeutics Inc   1.49 $ 238.552  Millions$ 160.340  Millions
Mirum Pharmaceuticals Inc   1.48 $ 330.728  Millions$ 222.788  Millions
Regeneron Pharmaceuticals Inc   1.45 $ 7,994.600  Millions$ 5,530.600  Millions
Imunon Inc   1.44 $ 6.900  Millions$ 4.779  Millions
Zai Lab Limited  1.44 $ 617.522  Millions$ 428.584  Millions
Mannkind Corporation  1.44 $ 205.271  Millions$ 142.898  Millions
Kyntra Bio Inc   1.41 $ 50.644  Millions$ 36.040  Millions
Medicus Pharma Ltd   1.40 $ 15.174  Millions$ 10.841  Millions
Aurinia Pharmaceuticals Inc   1.39 $ 179.732  Millions$ 129.084  Millions
Omeros Corporation  1.39 $ 131.953  Millions$ 94.963  Millions
Avenue Therapeutics Inc   1.38 $ 1.942  Millions$ 1.407  Millions
Royalty Pharma Plc  1.33 $ 836.986  Millions$ 630.928  Millions
Cormedix Inc   1.31 $ 256.692  Millions$ 196.535  Millions
Transcode Therapeutics Inc   1.30 $ 8.383  Millions$ 6.430  Millions
Elite Pharmaceuticals Inc   1.28 $ 39.032  Millions$ 30.442  Millions
Ani Pharmaceuticals Inc  1.27 $ 360.212  Millions$ 283.655  Millions
Pmgc Holdings Inc   1.25 $ 19.126  Millions$ 15.329  Millions
Petros Pharmaceuticals inc   1.23 $ 3.489  Millions$ 2.845  Millions
Nature s Sunshine Products inc   1.20 $ 82.503  Millions$ 68.745  Millions
Phathom Pharmaceuticals Inc   1.19 $ 182.478  Millions$ 153.777  Millions
Compass Pathways Plc  1.18 $ 433.720  Millions$ 367.285  Millions
Geovax Labs Inc   1.17 $ 3.163  Millions$ 2.712  Millions

Date modified: 2026-09-08T17:36:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.